FDA worries over personnel shortfall as review times suffer
This article was originally published in Clinica
Executive Summary
The US FDA is experiencing a serious brain drain that is already beginning to contribute to rising review times. The Office of Device Evaluation (ODE) alone has lost 31 staff in the last year many, coming within the pivotal divisions of Cardiovascular and Respiratory Devices.